Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q4 FY2023 Earnings Presentation
31 slides from Jubilant Ingrevia's earnings presentation, May 2023
Slide 1: Investor Presentation
Investor Presentation May 2023 Jubilant Ingrevia Limited 1
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Table of Contents
Company Snapshot - 04 Financial Highlights – Q4 & FY’23 - 08 Business Segments Overview - 12 Business Enablers Snapshot - 22 Table of Contents 3
Slide 4: Company Overview
Company Overview Jubilant Ingrevia Limited 4
Slide 5: Jubilant Bhartia Group - Snapshot
Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, CDMO (Contract Research & Development Services) and Therapeutics, Specialty Chemicals, Nutraceutical Prod
Slide 6: Company Snapshot
Company Snapshot Rs. 4,773 Cr Rs. 580 Cr Rs. 308 Cr Revenue FY23 EBITDA FY23 PAT FY23 Expertise in 35 technology 134+ platforms and multistep Catering to 1500+ customers products commercialized across business segments chemistry 6
Slide 7: Integrated Business Segments
Integrated Business Segments Jubilant Ingrevia Limited Specialty Chemicals Nutrition & Health Solutions Chemical Intermediates# • Pyridine & Picolines • Acetyls • Nutrition & Health Ingredients • Fine Chemicals • Specialty Ethanol • Crop Protection Chemicals • Animal & Human Nutrition Health Solutio
Slide 8: Financial Highlights Q4 & FY'23
Financial Highlights Q4 & FY’23 8
Slide 9: Chairmen's Message on Q4 & FY23 Financial Results
Chairmen’s Message on Q4 & FY23 Financial Results Mr. Shyam S Bhartia Mr. Hari S Bhartia Chairman Co-Chairman “We are happy to announce that during the year FY23 our Specialty chemicals business grew 29%, Chemical Intermediate business placed highest ever volume of Acetic Anhydride and gained higher
Slide 10: Financial Results Overview | Consolidated
Financial Results Overview | Consolidated Particulars1 Q4'FY22 Q4'FY23 Y-o-Y FY22 FY23 Y-o-Y Total Revenue 1,296 1,145 -12% 4,949 4773 -4% Total EBITDA 152 111 -27% 863 580 -33% EBITDA Margin (%) 11.7% 9.7% 17.4% 12.2% Profit After Tax 69 52 -24% 477 308 -35% Profit After Tax Margin (%) 5.3% 4.6% 9.
Slide 11: Key Ratios | As on 31st March 2023
Key Ratios| As on 31st March 2023 1 Particulars FY’2022 FY’2023 Net Debt 181 312 Net Debt to Equity 0.07x 0.12x Net Debt to EBITDA 0.21x 0.54x Working Captal to Turnover 16% 17% 1. All figures are in Rs Crore unless otherwise stated 11
Slide 12: Business Segments Overview
Business Segments Overview 12
Slide 13: Financials | Speciality Chemicals Segment
Financials | Speciality Chemicals Segment Particulars1 Q4'FY22 Q4'FY23 Y-o-Y FY22 FY23 Y-o-Y Segment Revenues 444 468 5% 1,393 1798 29% % Contribution to Revenues 34% 41% 28% 38% EBITDA 81 55 -32% 312 284 -9% % EBITDA Margins 18% 12% 22% 16% % Contribution to EBITDA 53% 50% 36% 49% 1. All figures ar
Slide 14: Business Highlights | Speciality Chemicals Segment
Business Highlights | Speciality Chemicals Segment • Business recorded good revenue growth in FY23 led by healthy volume growth. • Segment EBITDA & Margins during the year were impacted due to high Energy cost and headwinds faced in some of the Specialty products meant for Agrochemical customers • D
Slide 15: Business Segment Overview | Speciality Chemicals
Business Segment Overview | Speciality Chemicals 70+ Products (Pyridines & Picolines, Globally among Top 2 Globally lowest cost Serving 15 of top 20 Cyanopyridines, in (Pyridine+Beta); producer of Pyridine Global Pharma & 7 of Piperidines, Globally #1 in 18 offering significant top 10 Global Aminopy
Slide 16: Financial Highlights | Nutrition & Health Solutions
Financial Highlights |Nutrition & Health Solutions 1 Particulars Q4'FY22 Q4'FY23 Y-o-Y FY22 FY23 Y-o-Y Segment Revenues 206 155 -24% 767 551 -28% % Contribution to Revenues 16% 14% 16% 12% EBITDA 50 5 -90% 164 46 -72% % EBITDA Margins 24% 3% 21% 8% % Contribution to EBITDA 33% 4% 19% 8% 1. All figur
Slide 17: Business Highlights | Nutrition & Health Solutions
Business Highlights |Nutrition & Health Solutions • Business during the year impacted due to Avian and Swine Flu in EU and US regions, resulting into lower volume and significant price erosion of Niacinamide (Vitamin B3). • Niacinamide volumes improved sequentially during Q4. • Expect improvement in
Slide 18: Business Segment Overview | Nutrition & Health Solutions
Business Segment Overview | Nutrition & Health Solutions Catering to Varied End Use Industries, ranging from, Personal 5 Nutrition Ingredients Care, Pharmaceuticals and Animal Feed & Global top 2 in Full Backward 18+ branded solutions Vitamin B3 Intigration for Vitamin B3 via green Niainamide End Us
Slide 19: Financial Highlights | Chemical Intermediates
Financial Highlights | Chemical Intermediates 1 Particulars Q4'FY22 Q4'FY23 Y-o-Y FY22 FY23 Y-o-Y Segment Revenues 646 522 -19% 2,789 2423 -13% % Contribution to Revenues 50% 46% 56% 51% EBITDA 30 59 98% 417 283 -32% % EBITDA Margins 5% 11% 15% 12% % Contribution to EBITDA 20% 53% 48% 49% 1. All fig
Slide 20: Business Highlights | Chemical Intermediates
Business Highlights | Chemical Intermediates • Revenue for the year is lower on account of lower feed stock prices i.e. Acetic Acid, leading to lower price realization of both Acetic Anhydride & Ethyl Acetate. • EBITDA for the year is lower due to normalization of Acetic Anhydride market situation l
Slide 21: Business Segment Overview | Chemical Intermediates
Business Segment Overview | Chemical Intermediates Catering to Varied End Use Industries, most of these end use 9 Products having promising growth Acetic Anhydride: (Acetic Anhydride, Ethyl Globally No. 2 in Acetate ,Propionic Merchant Mkt Anhydride, Aldehydes, No.1 in India Speciality Alcohol, Expe
Slide 22: Business Enablers
Business Enablers Jubilant Ingrevia Limited 22
Slide 23: Key Technology Platforms
Research Development & Technology (RDT) Key Highlights 35 Key technology platforms developed & commercialized to global standards. Some 3 RDT centers in Noida, Gajraula and are unique: Ammoxidation, Grignard etc. Bharuch 114 highly qualified scientists (21 PhDs) 33 Products in Pipeline for next 4 ye
Slide 24: Multi Location Manufacturing & Operation Excellence
Multi Location Manufacturing & Operation Excellence Manufacturing Facilities 463 acres 310 acres 144 acres 109 acres 3.5 acres Gajraula, Uttar Pradesh, Bharuch, Gujarat, India India Speciality Chemicals, Integrated facility for Nutrition & Health Samlaya, Gujarat, India Ambernath, Maharashtra, Speci
Slide 25: Sustainability
Sustainability First time participated in S&P DJSI Assessment: Bharuch Nira Gajraula Global chemical industry's EHS initiative (Dec (Oct (Oct & Ethical framework towards safe chemicals • Achieved 95 percentile in the 2018) 2019) 2021) management and performance excellence Global Chemical Industry •
Slide 26: Bring Progressive Social Change via Strategic Multi-Stakeholder Partnerships
Bring Progressive Social Change via Strategic Multi-Stakeholder Partnerships Mission: To develop multi-stakeholder sustainable models to 1 Aspiring to touch the Lives Established Million bring about ‘social change’ involving knowledge generation through social initiatives in 2007 lives & sharing, ex
Slide 27: Annexure 1- Income Statement | Consolidated
Annexure 1- Income Statement | Consolidated Particulars1 Q4'FY22 Q4'FY23 YoY FY22 FY23 YoY Revenue from operations a) Sales/Income from operations 1276 1129 -11% 4914 4740 -4% b) Other operating income 20 16 -22% 35 32 -8% Total revenue from operations 1296 1145 -12% 4949 4773 -4% Other income 9 9 -
Slide 28: Annexure II: Income Statement Segmental – Q4 & FY23
Annexure II: Income Statement Segmental – Q4 & FY23 1 Particulars Q4'FY22 Q4'FY23 YoY (%) FY22 FY23 YoY (%) Total Revenue from Operations 1,296 1,145 (12%) 4,949 4,773 (4%) Speciality Chemicals 444 468 5% 1,393 1,798 29% Nutrition & Health Solutions 206 155 (24%) 767 551 (28%) Chemical Intermediates
Slide 29: Annexure III- Balance Sheet | As on 31st March 2023
Annexure III- Balance Sheet | As on 31st March 2023 Particulars1 31-Mar-22 31-Mar-23 Shareholders Fund 2,433 2,666 Non Current liabilities 311 413 Long Term Borrowings 100 150 Other Long Term Liabilities 212 263 Current Liabilities 1,053 1,180 Short Term Borrowings 129 247 Trade Payables 772 778 Oth
Slide 30: Thank you for your time
For More Information For Investors: Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pavleen Taneja Pharmaceutical, Nutrition, Agrochemical, Consumer and Jubilant Ingrevia Limited. Industrial customers with customised products and solut
Slide 31: Appendix III - Conference Call Details
Appendix III - Conference Call Details Date : May 16th, 2023 Diamond Pass Log-In Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, passc